Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

Launched by SHANGHAI ZHONGSHAN HOSPITAL · May 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medication called dihydroartemisinin (DHA) to see if it can help treat acne vulgaris, which is a common skin condition that causes pimples. The main goal of the study is to find out if taking DHA can reduce the severity of acne in adults. Participants in the trial will take DHA every day for three months and will visit the clinic once a month for checkups to monitor their progress.

To be eligible for this study, participants must have a diagnosis of acne vulgaris and, for women, should not plan to become pregnant in the next six months. Those who have recently used certain acne treatments or have serious health conditions affecting their vital organs cannot join. This trial is currently looking for participants of all genders, between the ages of 18 and 65. If you're interested, this could be an opportunity to explore a new treatment option for acne while contributing to important research!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinically diagnosed with acne vulgaris;
• • For female patients, no pregnancy plans within the next 6 months.
• Exclusion Criteria:
• • Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months;
• • Patients who have used topical medications for acne within the past 2 weeks;
• • Pregnant or breastfeeding women;
• • Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.